STL Volume 27 Number 6
Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis
Moderate to severe chronic plaque psoriasis may be difficult to control using current therapies, which has led to development of a novel class of therapy, selective tyrosine kinase 2 (TYK2) inhibitors, to address this unmet need.
Acne Scars: An Update on Management
Acne scars are a frequent complication that results from damage to the skin during the healing process of lesions, with studies indicating that 50% of those suffering from acne may develop scars.
Update on Drugs & Devices: November – December 2022
Update covering: Deucravacitinib tablets (Sotyktu™), DaxibotulinumtoxinA-lanm IM injection (Daxxify™), Dupilumab for SC injection (Dupixent®), Spesolimab-sbzo IV injection (Spevigo®) and Selumetinib capsules (Koselugo™).
